Ovid Therapeutics Inc

LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company based in New York, NY, focused on developing novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia and bipolar depression. The company's lead product candidate, LB102, is positioned to potentially become the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. The firm is actively building a pipeline that leverages the broad therapeutic potential of LB102, informed by peer-reviewed research and presentations. As LB Pharmaceuticals Inc advances its clinical efforts, it seeks to address unmet needs in mental health treatment through innovative approaches. Generated from the website

Neurogene Inc. is a clinical-stage company based in New York, NY, dedicated to developing life-changing genetic medicines for individuals and families affected by devastating neurological diseases. With a strong sense of purpose and a focus on innovation and scientific execution, Neurogene aims to harness the potential of gene therapy to revolutionize medical treatment. Driven by a commitment to addressing the high unmet need for rare neurological diseases, Neurogene is building a gene therapy pipeline to bring hope and relief to those impacted by these conditions. Through their clinical programs and resources, Neurogene strives to advance the field of genetic medicine and improve the lives of patients and their families.Generated from the website

Sumitovant Biopharma, Inc., based in New York, NY, is dedicated to improving global health by driving innovative treatments in critical areas such as psychiatry, neurology, oncology, urology, women's health, rare diseases, and cell gene therapy. Their diverse pipeline of preclinical and clinical programs aims to address high patient needs through a technology-driven approach. Sumitovant Biopharma, Inc., through its U.S. subsidiary, Sumitomo Pharma America, Inc., embodies a bold promise of combining technology and life-sciences expertise to deliver patient-first solutions faster and more efficiently, ultimately improving patient outcomes worldwide.Generated from the website